INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 136 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109,858 | -18.5% | 2,109 | -0.9% | 0.02% | -5.3% |
| Q2 2023 | $134,808 | +16.9% | 2,129 | 0.0% | 0.02% | +11.8% |
| Q1 2023 | $115,285 | +101027.2% | 2,129 | -1.2% | 0.02% | -5.6% |
| Q4 2022 | $114 | -100.0% | 2,155 | -93.5% | 0.02% | -78.8% |
| Q3 2018 | $724,000 | +28.1% | 33,384 | +4.3% | 0.08% | +19.7% |
| Q2 2018 | $565,000 | -2.2% | 32,000 | +16.6% | 0.07% | -6.6% |
| Q1 2018 | $578,000 | -55.1% | 27,443 | -67.5% | 0.08% | -63.3% |
| Q3 2016 | $1,288,000 | +100.9% | 84,488 | +411.3% | 0.21% | +93.5% |
| Q2 2016 | $641,000 | +25.0% | 16,524 | -10.5% | 0.11% | +21.6% |
| Q1 2016 | $513,000 | – | 18,457 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |